RT Journal Article
T1 MMP-7 and SGCE as distinctive molecular factors in sporadic colorectal cancers from the mutator phenotype pathway
A1 Ortega Molina, Soledad Paloma
A1 Morán, Alberto
A1 Fernández Marcelo, Tamara
A1 Juan Chocano, María Del Carmen De
A1 Frías, Cristina
A1 López Asenjo, JA
A1 Sánchez Pernaute, Andrés
A1 Torres García, Antonio José
A1 Díaz-Rubio García, Eduardo
A1 Iniesta Serrano, María Pilar
A1 Benito De Las Heras, Manuel R.
AB Colorectal cancers (CRCs) from the suppressor and the mutator carcinogenic pathways display distinctive pathological and clinical features that remain not completely understood. In this context, the aim of this work was to study the differential expression of metalloproteinases and adhesion molecules related to cancer invasiveness in both groups of tumours. We analyzed 84 tissue specimens, 42 primary sporadic CRCs obtained from patients who underwent radical surgery, and its corresponding control tissues. According to microsatellite instability, 31 cancers showed low or null microsatellite instability (MSI-L/MSS) and 11 tumours displayed high microsatellite instability (MSI-H). Expression assays were established using the Oligo GEArray® human extracellular matrix and adhesion molecules microarray containing 114 genes. Real-time quantitative PCR (RT-qPCR) confirmed expression data from arrays, using TaqMan probes. Results from oligoarray expression analyses indicated that ITGA3, ITGA9, ITGB4, ITGB7 and MMP15 had significantly higher expression levels in MSI-H tumours versus MSS/MSI-L cancers, whereas COL12A1, CSPG2, FN1, MMP-7 and SGCE were down-regulated in tumours with high microsatellite instability when compared to the stable group. After RT-qPCR validation, two of these genes, MMP-7 and SGCE, were confirmed to have statistical differences between the two groups of tumours studied. In both cases, MSI-H tumours displayed significant lower expression levels than MSI-L/MSS tumours. In conclusion, these two distinctive molecular markers could be related to a diminished invasion in colorectal tumours from the mutator pathway, this may contribute to the understanding of the better patient prognosis conferred by this type of tumours.
SN 1019-6439
SN 1791-2423
YR 2010
FD 2010-05-01
LK https://hdl.handle.net/20.500.14352/114602
UL https://hdl.handle.net/20.500.14352/114602
LA eng
NO Ministerio de Sanidad y Consumo (España)
NO Fundación de Investigación Médica Mutua Madrileña
DS Docta Complutense
RD 9 jun 2025